Hypolipidemics Market Report 2026

The hypolipidemics market size has grown steadily in recent years. It will grow from $31.91 billion in 2025 to $32.8 billion in 2026 at a compound annual growth rate (CAGR) of 2.8%. The growth in the historic period can be attributed to rising cardiovascular disease prevalence, widespread adoption of statins, increased cholesterol screening rates, improved access to essential cardiovascular drugs, expansion of hospital and pharmacy networks.

The hypolipidemics market size is expected to see steady growth in the next few years. It will grow to $37.34 billion in 2030 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to aging global population, rising incidence of dyslipidemia, increasing focus on preventive cardiology, growth in combination lipid therapies, expanding healthcare access in emerging markets. Major trends in the forecast period include rising long-term use of lipid-lowering therapies, increasing adoption of combination hypolipidemic drugs, growing focus on preventive cardiovascular pharmacotherapy, expansion of generic statin utilization, increased monitoring of cholesterol management outcomes.

Increasing incidences of obesity are expected to drive the growth of the hypolipidemic drugs market in the coming years. Obesity is a chronic metabolic disorder characterized by excessive accumulation of body fat, often resulting in elevated cholesterol levels, insulin resistance, and higher cardiovascular risk. The rise in obesity cases is mainly attributed to greater consumption of ultra-processed, calorie-dense foods, along with reduced physical activity associated with modern sedentary lifestyles. Hypolipidemic drugs are utilized in obesity to reduce elevated cholesterol levels, which can serve as a risk factor for cardiovascular complications in individuals with excess body fat. For example, in October 2025, Forbes, a US-based business media company, reported that the prevalence of adult obesity in the United States was 40.3%, with women at 41.3% and men at 39.2%, while the global prevalence of obesity among children and adolescents aged 5 to 19 years reached 9.4%. Consequently, rising incidences of obesity are fueling the expansion of the hypolipidemic drug market.

Major companies in the hypolipidemics market are concentrating on product innovation and new formulations, such as siRNA-based therapies that lower LDL cholesterol and are administered twice yearly, to enhance patient adherence, reduce treatment burden, and provide sustained lipid control with fewer injections. These therapies integrate powerful lipid-lowering mechanisms with convenient dosing schedules, addressing both clinical outcomes and patient quality of life. For example, in July 2025, Novartis, a Switzerland-based pharmaceutical firm, announced that its Leqvio (inclisiran) received FDA approval for first-line use in patients needing LDL-cholesterol reduction, enabling more patients to benefit from its twice-yearly dosing regimen. Inclisiran functions by silencing the PCSK9 gene in the liver through RNA interference, offering lasting LDL-lowering effects with only two doses annually. This approval highlights a trend in the hypolipidemics market toward long-acting, high-efficacy therapies that support long-term cardiovascular risk management without frequent dosing.

In July 2025, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Verve Therapeutics for approximately $1.5 billion. Through this acquisition, Eli Lilly intends to enhance its hypolipidemics portfolio by incorporating Verve’s gene-editing therapies, which are designed as one-time treatments for patients at high cardiovascular risk, including those with genetically elevated LDL cholesterol. Verve Therapeutics, a US-based biotechnology company, focuses on developing innovative gene-editing therapies targeting cardiovascular disease, including hypolipidemics.

Major companies operating in the hypolipidemics market are Pfizer Inc., AstraZeneca Plc, Novartis AG, Sanofi-Aventis, Merck Sharp & Dohme B.V., Amgen Plc, Abbott Laboratories Limited, Daiichi Sankyo Company Limited, Kowa Company Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Ltd., Cipla Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Ltd.

North America was the largest region in the hypolipidemic drugs market in 2025. The Middle East is expected to be the fastest-growing region in the hypolipidemic drugs market during the forecast period. The regions covered in the hypolipidemics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypolipidemics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the hypolipidemics market by increasing costs of imported active pharmaceutical ingredients used in statins, pcsk9 inhibitors, and bile acid sequestrants. The impact is most pronounced in hmg-coa reductase inhibitor and pcsk9 inhibitor segments, particularly in north america and europe where cross-border api sourcing is common. However, tariffs have supported domestic api manufacturing and strengthened regional pharmaceutical supply chains.

The hypolipidemics market research report is one of a series of new reports that provides hypolipidemics market statistics, including hypolipidemics industry global market size, regional shares, competitors with a hypolipidemics market share, detailed hypolipidemics market segments, market trends and opportunities, and any further data you may need to thrive in the hypolipidemics industry. This hypolipidemics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hypolipidemic drugs are substances that reduce the concentration of lipids and lipoproteins (lipid-protein complexes) in the blood. Lipoproteins can accumulate in the arteries and carry cholesterol. They are also known as lipid-lowering medications.

The main categories of hypolipidemic drugs include cholic acid regulators, HMG-CoA reductase inhibitors, adenylate cyclase inhibitors, nicotinic acid drugs, and others. HMG-CoA reductase inhibitors are lipid-lowering medications used for both the primary and secondary prevention of coronary heart disease. These drugs are utilized in hospitals, clinics, pharmacies, and cardiovasology. The various types of these medications include statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and others.

The hypolipidemic drugs market consists of sales of cholesterol absorption inhibitors, bile acid sequestrants, and fibric acid derivatives. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.